HC Wainwright & Co. Initiates Coverage of Autolus Therapeutics plc - Depositary Receipt (AUTL) with Buy Recommendation, Analyst Price Forecast Suggests 553.53% Upside

HC Wainwright & Co. initiates coverage of Autolus Therapeutics (AUTL) with a Buy recommendation. Analysts forecast a 553.53% upside from its current closing price of $1.40/share, with an average one-year price target of $9.15/share. The projected annual revenue is 306MM, an increase of 498.38%. Institutional ownership decreased by 13.71% to 165,285K shares.